Genmab — Juli 2019
-
i think it does have a bit more importance as
Madsen claims, referring to 22:49
/ Bulder yesterday evening. Cassiopeia was a big success at the last conferences, so it would be great if this Griffin data triggers reimbursement and allows MD's to start subscribing that combo -
Bulder, dit flottenheimer-fejende udsagn om at hex-cd38+Iberdomide er fremtiden, er Celgene heller ikke nødvendigvis uenige i ;-). Sidste afsnit af 1. sektion i Sukkers link http://www.firstwordpharma.com/node/1644686?tsid=33#axzz5tAYWytDY : "The phase 1/2 study is also evaluating iberdomide as monotherapy and in combination with daratumumab or bortezomib or carfilzomib."
-
"Genmab intends to use the net proceeds from the Offering to continue the development of its proprietary product candidates, to continue its pre-commercial activities, to continue building its commercial capabilities and to advance its earlier stage product candidates."
-
-
Ja, jeg kan altså ikke se det som andet end rettidig omhu.. uanset at tøserne herinde hyler og skriger: "Hvad i alverden skal de bruge alle de, overflødige, penge til?". Til dette kan man bare, belærende
, sige: udvikling af biokemiske stoffer er svinedyrt og tager langt tid. Eller: det er altid bedre at have 110 kr end 100 kr på kontoen - den kender og forstår alle vel?!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind